Chantal Gauthier, Benjamin Lauzier, Jean-Noël Trochu

Heart failure with the preserved ejection fraction (HFpEF), which currently accounts for 50% of all HF patients, has become a major clinical problem without effective treatment. Using our HFpEF animal model (beta3-receptor-overexpressing rat) and blood of patients suffering from HFpEF (cohort and biocollection under construction), our aims are to identify biomarkers and molecular targets relevant to this major cardiovascular burden.